Please login to the form below

Not currently logged in
Email:
Password:

Ixempra

This page shows the latest Ixempra news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

Bayer fails to overturn Nexavar compulsory licence in India

drugs. There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down

Latest news

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... According to the Indian Express, Herceptin, Ixempra and Sprycel cost 50, 000 rupees (687), 70, 000-80, 000 rupees (961 to 1, 098) and 15, 000 rupees (206)

  • Eisai wins approval for breast cancer drug

    and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

  • Bristol-Myers signs cancer drug deal

    BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).

  • FDA approves BMS chemotherapy drug

    Ixempra was approved for use in women who have failed treatment on three other types of chemotherapy. ... Ixempra inhibits the protein tubulin, which stops cells growing and dividing by arresting the cell cycle.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics